Stanford Study Identifies Why Ozempic and Wegovy Don’t Work in About 1 in 10 Patients

A Stanford Medicine study identifies a genetic variant in about 10% of people that may reduce response to GLP-1 drugs like Ozempic and Wegovy, offering new insight into why these widely used diabetes and weight-loss treatments fail for some patients and highlighting the future of precision medicine in Type 2 diabetes care.